Supernus Pharmaceuticals, Inc.
SUPN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001356576
No open-market purchases or sales by Supernus Pharmaceuticals, Inc. insiders were filed in the last 90 days; 334 institutions reported holding it in 13F filings for Q2 2026, worth $2.80B in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +11 vs. previous quarter
- 334
- 13F valueReported value at the end of Q2 2026
- $2.80B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding SUPN, Q2 2026
No superinvestor reported holding SUPN at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Supernus Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Mar 18, 2026 (view filing) | Mar 16-18 | 2 days | Bhatt Padmanabh P.Sr. VP of IP, CSO | SSale | −107.3K | $50.24 | −$5.39M | −86.3%17.0K after | 6 lots10b5-1 |
| Mar 16, 2026 (view filing) | Mar 13 | 3 days | Khattar Jack A.President, CEO | SSale | −35.0K | $50.37 | −$1.76M | −3.5%958.1K after | 3 lots10b5-1 |
| Mar 16, 2026 (view filing) | Mar 12 | 4 days | Hudson Frederick M.Director | SSale | −5.37K | $50.61 | −$271.7K | −8.2%60.4K after | |
| Mar 10, 2026 (view filing) | Mar 9-10 | 1 day | Horich William ToddSVP, Commercial Operations | SSale | −8.88K | $54.50 | −$483.8K | −100.0%0 after | 2 lots |
| Mar 10, 2026 (view filing) | Mar 9 | 1 day | Mottola FrankSVP, Chief Tech. Ops. Officer | SSale | −1.62K | $53.65 | −$87.1K | −8.1%18.4K after | |
| Mar 9, 2026 (view filing) | Mar 5-6 | 4 days | Gemayel GeorgesDirector | SSale | −18.8K | $53.38 | −$1.00M | −40.8%27.3K after | 2 lots |
| Feb 23, 2026 (view filing) | Feb 19 | 4 days | Sensenig BethanyDirector | SSale | −4.47K | $51.01 | −$228.3K | −100.0%0 after | 2 lots10b5-1 |
| Dec 22, 2025 (view filing) | Dec 19 | 3 days | Mottola FrankSVP, Chief Tech. Ops. Officer | SSale | −20.0K | $50.41 | −$1.01M | −56.3%15.5K after | 2 lots10b5-1 |
| Dec 19, 2025 (view filing) | Dec 18 | 1 day | Bhatt Padmanabh P.Sr. VP of IP, CSO | SSale | −710 | $44.44 | −$31.6K | −4.7%14.5K after | |
| Oct 10, 2025 (view filing) | Oct 9 | 1 day | Khattar Jack A.President, CEO | SSale | −59.9K | $50.57 | −$3.03M | −4.7%1.21M after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Supernus Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 9,350,046 | $434.9M | 0.01% | +552,792+6.3% | Added |
| Millennium Management LLC | 3,853,212 | $179.2M | 0.12% | +537,239+16.2% | Added |
| Vanguard Portfolio Management LLC | 3,305,429 | $153.7M | 0.01% | +66,736+2.1% | Added |
| Armistice Capital, LLC | 2,646,201 | $123.1M | 3.40% | +750,854+39.6% | Added |
| Vanguard Capital Management LLC | 2,516,721 | $117.1M | 0.00% | +49,506+2.0% | Added |
| State Street Corp | 2,459,828 | $114.4M | 0.00% | +171,701+7.5% | Added |
| Nomura Asset Management International Inc. | 2,378,329 | $110.6M | 0.17% | +341,127+16.7% | Added |
| Dimensional Fund Advisors LP | 2,078,090 | $96.7M | 0.02% | −228,940−9.9% | Reduced |
| Geode Capital Management, LLC | 1,570,088 | $73.0M | 0.00% | −53,426−3.3% | Reduced |
| Stephens Investment Management Group LLC | 1,485,821 | $69.1M | 0.74% | +134,490+10.0% | Added |